NO962637L - 2,4-disulfonylfenylbutylnitron, salter derav og anveldelse som farmasöytiske midler - Google Patents

2,4-disulfonylfenylbutylnitron, salter derav og anveldelse som farmasöytiske midler

Info

Publication number
NO962637L
NO962637L NO962637A NO962637A NO962637L NO 962637 L NO962637 L NO 962637L NO 962637 A NO962637 A NO 962637A NO 962637 A NO962637 A NO 962637A NO 962637 L NO962637 L NO 962637L
Authority
NO
Norway
Prior art keywords
nervous system
central nervous
pharmaceutical agents
salts
disulfonylphenylbutylnitrone
Prior art date
Application number
NO962637A
Other languages
English (en)
Other versions
NO962637D0 (no
NO306457B1 (no
Inventor
John M Carney
Original Assignee
Oklahoma Med Res Found
Univ Kentucky Res Found
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Oklahoma Med Res Found, Univ Kentucky Res Found filed Critical Oklahoma Med Res Found
Publication of NO962637D0 publication Critical patent/NO962637D0/no
Publication of NO962637L publication Critical patent/NO962637L/no
Publication of NO306457B1 publication Critical patent/NO306457B1/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C309/00—Sulfonic acids; Halides, esters, or anhydrides thereof
    • C07C309/01—Sulfonic acids
    • C07C309/28—Sulfonic acids having sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
    • C07C309/45—Sulfonic acids having sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton containing nitrogen atoms, not being part of nitro or nitroso groups, bound to the carbon skeleton
    • C07C309/46—Sulfonic acids having sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton containing nitrogen atoms, not being part of nitro or nitroso groups, bound to the carbon skeleton having the sulfo groups bound to carbon atoms of non-condensed six-membered aromatic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/06—Free radical scavengers or antioxidants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biochemistry (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Toxicology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Hydrogenated Pyridines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
NO962637A 1993-12-23 1996-06-20 2,4-disulfonylfenylbutylnitron, salter derav, farmasöytisk sammensetning, samt anvendelse av denne forbindelse til fremstilling av et medikament NO306457B1 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/173,579 US5488145A (en) 1993-12-23 1993-12-23 2,4-disulfonyl phenyl butyl nitrone, its salts, and their use as pharmaceutical free radical traps
PCT/US1994/014545 WO1995017876A2 (en) 1993-12-23 1994-12-22 2,4-disulphophenyl butylnitrone, its salts, and their use as pharmaceutical spintraps

Publications (3)

Publication Number Publication Date
NO962637D0 NO962637D0 (no) 1996-06-20
NO962637L true NO962637L (no) 1996-08-13
NO306457B1 NO306457B1 (no) 1999-11-08

Family

ID=22632663

Family Applications (1)

Application Number Title Priority Date Filing Date
NO962637A NO306457B1 (no) 1993-12-23 1996-06-20 2,4-disulfonylfenylbutylnitron, salter derav, farmasöytisk sammensetning, samt anvendelse av denne forbindelse til fremstilling av et medikament

Country Status (29)

Country Link
US (4) US5488145A (no)
EP (1) EP0736004B1 (no)
JP (3) JP3412821B2 (no)
KR (1) KR100370522B1 (no)
CN (1) CN1070176C (no)
AT (1) ATE192736T1 (no)
AU (1) AU679835B2 (no)
BR (2) BR9408378A (no)
CA (1) CA2179521C (no)
CZ (1) CZ289629B6 (no)
DE (1) DE69424441T2 (no)
DK (1) DK0736004T3 (no)
ES (1) ES2145264T3 (no)
FI (1) FI111718B (no)
GR (1) GR3034134T3 (no)
HK (2) HK1001768A1 (no)
HR (1) HRP950358B1 (no)
HU (1) HU221167B1 (no)
MY (1) MY114178A (no)
NO (1) NO306457B1 (no)
NZ (1) NZ279025A (no)
PL (1) PL185189B1 (no)
PT (1) PT736004E (no)
RU (1) RU2159231C2 (no)
SG (1) SG64903A1 (no)
SK (1) SK282403B6 (no)
TW (1) TW299315B (no)
UA (1) UA45964C2 (no)
WO (1) WO1995017876A2 (no)

Families Citing this family (64)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5723502A (en) * 1985-07-18 1998-03-03 Proctor; Peter H. Topical spin trap composition and method
EP0496796B1 (en) * 1989-10-17 1994-08-31 Oklahoma Medical Research Foundation Method and compositions for inhibition of disorders associated with oxidative damage
US5622994A (en) * 1989-10-17 1997-04-22 Oklahoma Medical Research Foundation Spin trapping pharmaceutical compositions and methods for use thereof
US6002001A (en) * 1991-06-18 1999-12-14 Oklahoma Medical Research Foundation Spin trapping pharmaceutical compositions and methods for use thereof
US20050107366A1 (en) * 1991-06-18 2005-05-19 Carney John M. Spin trapping pharmaceutical compositions and methods for use thereof
US20040208875A1 (en) * 1995-03-15 2004-10-21 Queen's University At Kingston Method for treating amyloidosis
US5488145A (en) * 1993-12-23 1996-01-30 Oklahoma Medical Research Foundation 2,4-disulfonyl phenyl butyl nitrone, its salts, and their use as pharmaceutical free radical traps
DE69625701T2 (de) * 1995-09-11 2003-10-02 Aventis Pharma Inc Cyclische nitrone und pharmazeutische zusammensetzungen die sie enthalten
EP0888290B1 (en) 1995-11-17 2006-12-27 Florida International University Azulenyl nitrone spin trapping agents, methods of making and using same
NZ332315A (en) * 1996-04-17 2000-03-27 Centaur Pharmaceuticals Inc Nitrone free radical trapping compounds and their use in the treatment of dementia associated with aids virus (HIV-1) infection
EP1021430A1 (en) * 1996-07-19 2000-07-26 Centaur Pharmaceuticals, Inc. Furan nitrone compounds
TW429241B (en) * 1996-09-26 2001-04-11 Sumitomo Pharma Nitrone derivatives
MA26553A1 (fr) 1997-10-17 2004-12-20 Centaur Pharmaceuticals Inc Alpha-aryl-n-alkylnitrones et compositions pharmaceutiques contenant ceux-la
DE69904018D1 (en) * 1998-01-16 2003-01-02 Centaur Pharmaceuticals Inc Thiophennitronderivate
ZA99252B (en) * 1998-01-16 1999-07-14 Centaur Pharmaceuticals Inc Thioether furan nitrone compounds.
WO1999045909A2 (en) * 1998-03-13 1999-09-16 Centaur Pharmaceuticals Use of nitrone compounds for the inhibition of angiogenesis
CA2333190A1 (en) * 1998-05-19 1999-11-25 Beverly Greenwood-Van Meerveld Furan nitrone therapeutics for the treatment of inflammatory bowel disease
US6083989A (en) * 1999-05-18 2000-07-04 Centaur Pharmaceuticals, Inc. Aryl nitrone therapeutics for the treatment of inflammatory bowel disease
UA66401C2 (en) 1998-12-02 2004-05-17 Sentor Pharmaceuticals Inc 3,4,5-trisubstituted aryl nitrone compounds and pharmaceutical composition containing the same
US6730700B2 (en) 1998-12-02 2004-05-04 Renovis, Inc. 3,4,5,-trisubstituted aryl nitrone compounds and pharmaceutical compositions containing the same
JP4501128B2 (ja) 1999-01-25 2010-07-14 ナショナル ジュウィッシュ ヘルス 置換ポルフィリン
WO2000064420A2 (en) * 1999-04-28 2000-11-02 Queen's University At Kingston Compositions and methods for treating amyloidosis using sulphonate derivatives
BR9904931A (pt) * 1999-10-18 2001-06-12 Sergio Teixeira Ferreira Inibição de amiloidoses
US6815425B1 (en) 1999-10-22 2004-11-09 The United States Of America As Represented By The Secretary Of The Army Pharmaceutical composition containing pGLU-GLU-PRO-NH2 and method for treating diseases and injuries to the brain, spinal cord and retina using same
AU1574701A (en) * 1999-10-22 2001-04-30 Wrair Walter Reed Army Institute Of Research A pharmaceutical composition containing pglu-glu-pro-nh2 and method for treating diseases and injuries to the brain, spinal cord and retina using same
SE0000056D0 (sv) * 2000-01-10 2000-01-10 Astrazeneca Ab Novel process
SE0000055D0 (sv) 2000-01-10 2000-01-10 Centaur Pharmaceuticals Inc Novel process
AU2001236442A1 (en) * 2000-01-10 2001-07-24 Centaur Phamaceuticals, Inc. Method for the purification of aryl sulfonic acids and salts
SE0001916D0 (sv) * 2000-05-23 2000-05-23 Astrazeneca Ab Novel formulation
US6664297B1 (en) 2000-10-18 2003-12-16 Universidade Federal Do Rio De Janeiro Methods for inhibition and dissolution of amyloidoses by administration of compositions comprising 2,4-dinitrophenol
AU2002253857A1 (en) 2001-01-08 2002-09-04 Centaur Pharmaceuticals, Inc. Use of aryl nitrone compounds in methods for treating neuropathic pain
WO2003010154A1 (en) * 2001-07-26 2003-02-06 Samsung Electronics Co. Ltd. Seleno compounds containing nitrone moiety, their preparation and their therapeutic uses
US20030045461A1 (en) * 2001-09-06 2003-03-06 Jen-Chang Hsia Composition and methods of esterified nitroxides gated with carboxylic acids
FR2846968B1 (fr) * 2002-11-08 2005-02-04 Salles Jean Pierre Nouveaux derives amphiphiles de l'alpha-c-phenyl-n-tert- butyl nitrone
US7414076B2 (en) * 2003-06-23 2008-08-19 Neurochem (International) Limited Methods and compositions for treating amyloid-related diseases
US7244764B2 (en) * 2003-06-23 2007-07-17 Neurochem (International) Limited Methods and compositions for treating amyloid-related diseases
US20070010573A1 (en) * 2003-06-23 2007-01-11 Xianqi Kong Methods and compositions for treating amyloid-related diseases
US20050059638A1 (en) * 2003-08-04 2005-03-17 Kelly Michael G. Aryl, heteroaromatic and bicyclic aryl nitrone compounds, prodrugs and pharmaceutical compositions of the same to treat human disorders
US20050182060A1 (en) * 2004-02-13 2005-08-18 Kelly Michael G. 2-Substituted and 4-substituted aryl nitrone compounds
WO2006059252A2 (en) * 2004-11-12 2006-06-08 Neurochem (International) Limited Methods and fluorinated compositions for treating amyloid-related diseases
JP2008520647A (ja) * 2004-11-16 2008-06-19 ニューロケム （インターナショナル） リミテッド Ｃｎｓおよびアミロイド関連疾患治療のための化合物
CA2900876A1 (en) 2004-12-22 2006-08-17 Bhi Limited Partnership Methods and compositions for treating amyloid-related diseases
US20060235370A1 (en) * 2005-04-04 2006-10-19 Oblong John E Method of regulating mammalian keratinous tissue
TW200716088A (en) * 2005-04-15 2007-05-01 Neurochem Int Ltd Formulations and methods for treating amyloidosis
WO2007013843A1 (en) * 2005-07-26 2007-02-01 Astrazeneca Ab Use of 4-[(tert-butylimino)methyl]benzene-1,3-disulfonate n-oxide against myocardial ischaemia
WO2007013841A1 (en) * 2005-07-26 2007-02-01 Astrazeneca Ab Use of 4-((tert-butylimine)methyl) benzene-1,3-disulfonate n-oxide against cerebral oedema
WO2007013842A1 (en) * 2005-07-26 2007-02-01 Astrazeneca Ab Use of 4-((tert-butylimino)methyl) benzene-1,3-disulfonate n-oxide against maemorrhagic changes in the brain
WO2007013844A1 (en) * 2005-07-26 2007-02-01 Astrazeneca Ab Use of 4-[(tert-butylimino)benzene-1,3-disulfonate n-oxide against nausea
AU2006342958A1 (en) * 2005-12-22 2007-11-08 Bellus Health (International) Limited Treatment of renal disorders, diabetic nephropathy and dyslipidemias
WO2008013866A2 (en) * 2006-07-25 2008-01-31 Hough Ear Institute Methods for treating acute acoustic trauma
WO2009019534A2 (en) 2006-10-12 2009-02-12 Bellus Health (International) Limited Methods, compounds, compositions and vehicles for delivering 3-amino-1-propanesulfonic acid
EP2120905A1 (en) * 2006-12-22 2009-11-25 BELLUS Health (International) Limited Methods, compounds, and compositions for treating metabolic disorders and diabetes
US20090082454A1 (en) * 2007-09-25 2009-03-26 Protia, Llc Deuterium-enriched disufenton
EP3028670B1 (en) 2007-09-26 2023-12-20 St. Jude Medical, LLC Collapsible prosthetic heart valves
US8227517B2 (en) * 2008-02-12 2012-07-24 Tosk, Incorporated Doxorubicin adjuvants to reduce toxicity and methods for using the same
EP2300003B1 (en) * 2008-05-23 2014-03-05 National Jewish Health Compounds for use in treating injury associated with exposure to an alkylating species
WO2010028058A1 (en) * 2008-09-02 2010-03-11 Oklahoma Medical Research Foundation 2, 4-disulfonyl pheny tert-butyl nitrone for the treatment of gliomas
JP5762414B2 (ja) * 2009-08-24 2015-08-12 ハフ イヤ インスティテュート 急性音響外傷の治療方法
EP2670403B1 (en) 2011-02-04 2021-08-18 Hough Ear Institute Methods for treating brain injury
CN110248650A (zh) 2016-10-31 2019-09-17 霍夫耳科研究所 用于增强突触发生和神经突发生的方法
US11020354B2 (en) 2017-01-19 2021-06-01 Otologic Pharmaceuticals, Inc. Formulations of n-acetylcysteine and uses thereof
KR20200055722A (ko) * 2017-09-20 2020-05-21 오클라호마 메디컬 리써치 화운데이션 약물 내성 신경아교종의 치료
US10829441B2 (en) 2017-11-14 2020-11-10 The University Of Toledo Reactive oxygen species-sensitive nitric oxide synthase inhibitors for the treatment of ischemic stroke
JP2021523126A (ja) 2018-05-03 2021-09-02 ハフ イアー インスティテュート 蓄積した病理学的Ｔａｕタンパク質を低減する方法

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5036097A (en) * 1989-10-17 1991-07-30 Oklahoma Medical Research Foundation Phenylbutyl nitrone compositions and methods for prevention of gastric ulceration
US5025032A (en) * 1989-10-17 1991-06-18 Oklahoma Medical Research Foundation Phenyl butyl nitrone compositions and methods for treatment of oxidative tissue damage
EP0496796B1 (en) * 1989-10-17 1994-08-31 Oklahoma Medical Research Foundation Method and compositions for inhibition of disorders associated with oxidative damage
ATE209908T1 (de) * 1991-06-18 2001-12-15 Oklahoma Med Res Found RADIKALFÄNGER (ßSPIN TRAPSß) ZUR BEHANDLUNG VON MIT OXIDATION VON LIPIDEN UND PROTEINEN VERBUNDENEN ERKRANKUNGEN
US5488145A (en) * 1993-12-23 1996-01-30 Oklahoma Medical Research Foundation 2,4-disulfonyl phenyl butyl nitrone, its salts, and their use as pharmaceutical free radical traps

Also Published As

Publication number Publication date
FI111718B (fi) 2003-09-15
HU9601739D0 (en) 1996-08-28
DE69424441D1 (de) 2000-06-15
US5780510A (en) 1998-07-14
JP3412821B2 (ja) 2003-06-03
NO962637D0 (no) 1996-06-20
KR100370522B1 (ko) 2003-05-16
JP2001010953A (ja) 2001-01-16
FI962589A (fi) 1996-08-20
DE69424441T2 (de) 2000-10-12
BR1100626A (pt) 1999-11-23
EP0736004B1 (en) 2000-05-10
PL185189B1 (pl) 2003-03-31
EP0736004A1 (en) 1996-10-09
NO306457B1 (no) 1999-11-08
CZ289629B6 (cs) 2002-03-13
WO1995017876A2 (en) 1995-07-06
CA2179521C (en) 2002-03-19
NZ279025A (en) 1998-02-26
AU1552795A (en) 1995-07-17
HU221167B1 (en) 2002-08-28
AU679835B2 (en) 1997-07-10
CN1156447A (zh) 1997-08-06
PL315154A1 (en) 1996-10-14
WO1995017876A3 (en) 1995-08-10
HK1008294A1 (en) 1999-05-07
PT736004E (pt) 2000-09-29
US5508305A (en) 1996-04-16
JPH09507232A (ja) 1997-07-22
HRP950358B1 (en) 2001-04-30
CZ177596A3 (en) 1996-12-11
BR9408378A (pt) 1997-08-19
UA45964C2 (uk) 2002-05-15
US5488145A (en) 1996-01-30
HUT76788A (en) 1997-11-28
CA2179521A1 (en) 1995-07-06
FI962589A0 (fi) 1996-06-20
HK1001768A1 (en) 1998-07-10
SK78896A3 (en) 1997-09-10
RU2159231C2 (ru) 2000-11-20
JP2004075696A (ja) 2004-03-11
ES2145264T3 (es) 2000-07-01
ATE192736T1 (de) 2000-05-15
DK0736004T3 (da) 2000-10-09
US5475032A (en) 1995-12-12
MY114178A (en) 2002-08-30
GR3034134T3 (en) 2000-11-30
CN1070176C (zh) 2001-08-29
TW299315B (no) 1997-03-01
HRP950358A2 (en) 1997-08-31
SK282403B6 (sk) 2002-01-07
SG64903A1 (en) 1999-05-25

Similar Documents

Publication Publication Date Title
NO962637D0 (no) 2,4-disulfonylfenylbutylnitron, salter derav og anveldelse som farmasöytiske midler
DE69331409D1 (de) Oral 1alpha-hydroxyprevitamin d
NZ512883A (en) 2-oxoquinoline compounds and medicinal uses thereof
UA29469C2 (uk) Ліпосомальна фармацевтична композиція для внутрішньовенного введення
HK1045113A1 (zh) 給予固定的曲馬朵和雙氯酚酸組合的口服給藥形式
ES2147788T3 (es) 3,4-diarilcromanos para el tratamiento de la dermatitis.
ES2062137T3 (es) Utilizacion de 5'-deoxi-5'-metil-tioadenosina, s-adenosilmetionina y sus sales para la preparacion de composiciones farmaceuticas reductoras de seborrea.
HUP0204391A2 (en) The use of mirtazapine for the preparation of pharmaceutical composition suitable for the treatment of sleep disorders
NO955313L (no) Anvendelse av ropivacain i fremstillingen av et farmasöytikum med analgetisk effekt som har minimal motorisk blokkering
DK0742716T3 (da) Farmaceutisk sammensætning til systemisk transdermal indgivelse med det aktive middel morphin-6-glucuronid
AR035986A1 (es) Uso de derivados anti-convulsivos para la manufactura de un medicamento util para el tratamiento del temblor esencial
FR2818147B1 (fr) Nouvelle application therapeutique d'un derive de la thienyclyclohexylamine
ITMI922040A1 (it) Composizioni farmaceutiche per il trattamento di stati di iperaggregabilita' piastrinica